Staquis (crisaborole)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- crisaborole
- Company
- Pfizer Europe MA EEIG
- Status
- Withdrawn
- Therapeutic area
- Dermatitis, Atopic
- CHMP opinion
- Thu 30 Jan 2020
- EU approval
- Fri 27 Mar 2020
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004863
- ATC
- D11AH06
- Official record
- www.ema.europa.eu
Indication
Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ? 40% body surface area (BSA) affected.
Regulatory milestones
No milestones recorded in the last year.
Follow Staquis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.